Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Background: The no-reflow phenomenon refers to the absence of microvascular reperfusion
despite macrovascular reperfusion. Aim: The aim of this analysis was to summarize the …

Background The benefit of combined treatment with intravenous thrombolysis before
endovascular thrombectomy in patients with acute ischaemic stroke caused by large vessel …

Background Intravenous thrombolysis is recommended before endovascular treatment, but
its value has been questioned in patients who are admitted directly to centres capable of …

Background Current evidence supports the use of intravenous thrombolysis with alteplase in
patients with wake-up stroke selected with MRI or perfusion imaging and is recommended in …

卒中是致残和致死的主要疾病之一, 急性缺血性卒中约占全部卒中的80%.
急性缺血性卒中治疗的关键在于尽早开通阻塞血管, 挽救缺血半暗带. 目前被证实有效的急性缺 …

Importance The benefit of intravenous thrombolysis (IVT) for acute ischemic stroke declines
with longer time from symptom onset, but it is not known whether a similar time dependency …

The management of acute ischemic stroke has undergone a paradigm shift in the past
decade. This has been spearheaded by the emergence of endovascular thrombectomy …

Background Whether intravenous thrombolysis (IVT) prior to endovascular thrombectomy
(EVT) provides additional benefits in patients with acute ischemic stroke (AIS) and a large …

The last decade's progress in demonstrating the clinical benefit of endovascular
thrombectomy (EVT) in patients with large vessel occlusion stroke has transformed the …